{
  "updated_at": "2025-09-18 16:41 EDT",
  "holdings": [
    {
      "symbol": "ALDX",
      "name": "Aldeyra Therapeutics",
      "shares": 50,
      "avg_cost": 5.0,
      "last_price": 5.01,
      "stop": null,
      "catalyst": "FDA decision (PDUFA) Dec 16, 2025",
      "notes": "Hold through catalyst; consider profit-taking post-approval spike."
    },
    {
      "symbol": "ATYR",
      "name": "aTyr Pharma",
      "shares": 30,
      "avg_cost": 5.0,
      "last_price": 1.05,
      "stop": null,
      "catalyst": "Phase 3 top-line data expected Q3 2025",
      "notes": "Binary event; smaller size to manage risk."
    },
    {
      "symbol": "UAMY",
      "name": "United States Antimony",
      "shares": 34,
      "avg_cost": 2.94,
      "last_price": 5.89,
      "stop": 2.35,
      "catalyst": "Q2 2025 earnings; EV/critical minerals momentum",
      "notes": "Use trailing stop ~20%."
    },
    {
      "symbol": "CASH",
      "name": "Cash",
      "amount": 50.0
    }
  ]
}